Share on StockTwits
 

GlaxoSmithKline (LON:GSK)‘s stock had its “neutral” rating reaffirmed by analysts at Citigroup Inc. in a research report issued to clients and investors on Wednesday, Stock Ratings Network.com reports. They currently have a GBX 1,810 ($29.70) price objective on the stock. Citigroup Inc.’s price objective suggests a potential upside of 9.66% from the stock’s previous close.

GlaxoSmithKline (LON:GSK) traded up 0.46% on Wednesday, hitting GBX 1650.4999. The stock had a trading volume of 6,222,315 shares. GlaxoSmithKline has a 52-week low of GBX 1444.50 and a 52-week high of GBX 1816.00. The stock’s 50-day moving average is GBX 1606. and its 200-day moving average is GBX 1617.. The company’s market cap is £79.075 billion.

GSK has been the subject of a number of other recent research reports. Analysts at Panmure Gordon reiterated a “hold” rating on shares of GlaxoSmithKline in a research note on Thursday, February 6th. They now have a GBX 1,750 ($28.71) price target on the stock. Separately, analysts at UBS AG reiterated a “neutral” rating on shares of GlaxoSmithKline in a research note on Thursday, February 6th. They now have a GBX 1,650 ($27.07) price target on the stock. Finally, analysts at BNP Paribas reiterated an “underperform” rating on shares of GlaxoSmithKline in a research note on Thursday, February 6th. They now have a GBX 1,600 ($26.25) price target on the stock. Four research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of GBX 1,720.38 ($28.23).

GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.